Showing 2231-2240 of 2973 results for "".
- Scott Peterson, PhD is Now Head of Medical Affairs at Evolushttps://modernaesthetics.com/news/scott-peterson-phd/2472004/R. Scott Peterson, PhD is now Head of Medical Affairs at Evolus, supporting the strategic development and execution of medical affairs initiatives. Evolus is a company dedicated to aestheti
- Bellus Recognized with Multiple Aesthetic Awardshttps://modernaesthetics.com/news/bellus-recognized-with-multiple-aesthetic-awards/2472006/Bellus Medical topped the charts in eight categories presented by the 2018 Aesthetic Everything® Awards: · Top Aesthetic Companies · Top Skin Care Devices (SkinPen&r
- xMedica Launches Aesthetics Conference Focused on Energy Based Treatments for Male and Female Sexual Wellnesshttps://modernaesthetics.com/news/xmedica-launches-aesthetics-conference-focused-on-energy-based-treatments-for-male-and-female-sexual-wellness/2472007/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- ARTAS iX: Real-World Evaluation Study Shows Benefithttps://modernaesthetics.com/news/artas-ix-real-world-evaluation-study-shows-benefit/2472009/Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study of The new ARTAS iX™ Robotic Hair Restoration System demonstrates clinical efficiency in hair harvesting and implan
- Galderma Announces the Start of Six New Aesthetic Studieshttps://modernaesthetics.com/news/galderma-announces-the-start-of-six-new-aesthetic-studies/2472014/Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and
- Introducing Juvéderm It, Allergan's Newest Ad Campaignhttps://modernaesthetics.com/news/introducing-juvderm-it-allergans-newest-ad-campaign/2472020/Allergan plc is rolling out a new Juvéderm advertising campaign that aims to make this family of fillers a household name. Comprising a modernized logo, a bright, poppy color scheme, an edgy soundtrack and robust social media component, Juvéderm It is the first new adv
- RealSelf: One in Three U.S. Adults are Considering Nips/Tuckshttps://modernaesthetics.com/news/realself-one-in-three-us-adults-are-considering-nipstucks/2472025/One in three adults (37 percent) in the U.S. are considering at least one cosmetic treatment in the next 12 months, with significantly more considering nonsurgical procedures (34 percent) than surgical ones (24 percent), according to the
- ASPS Members Identify Key Plastic Surgery Trendshttps://modernaesthetics.com/news/asps-members-identify-key-plastic-surgery-trends/2472027/Breast augmentation, tummy tucks and liposuction will be the three most popular plastic surgery procedures in 2019, plastic surgeons predict. With regard to minimally invasive procedures, Botox still leads the way as the most anticipated request, followed by fillers, chemical peels, laser
- Special Report: Behind Allergan's and Bonti's Headline-Making Dealhttps://modernaesthetics.com/news/special-report-behind-allergans-and-bontis-headline-making-deal/2472032/The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins— Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001—were coming down the pike. Industry watchers were abuzz with predictions about which toxin
- New for EBD-Based Acne Care: Sebacia Microparticles Clearedhttps://modernaesthetics.com/news/new-for-ebd-based-acne-care-sebacia-microparticles-cleared/2472033/Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Sebacia, Inc. had submitted its 510(k) submission to the FDA in June 2018. Sebacia Mic